NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease; a prospective randomized trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519051-28-01

Enrollment

448

Registered

2025-02-14

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Type 2

Brief summary

Combined endpoint based on the first occurrence of cardiac death and cardiac hospitalization.

Detailed description

All cardiac hospitalization, Heart failure hospitalization, All cause hospitalization, NT-proBNP, Other predefined (see section plasma and serum biomarkers) biomarkers, Health economic analysis (cost-effectiveness of intervention considering both life- years and quality of life adjusted life years)

Interventions

DRUGEPROSARTAN

DRUGZOFENOPRIL

DRUGQUINAPRIL

DRUGRAMIPRIL

DRUGFOSINOPRIL

DRUGCARVEDILOL

DRUGNEBIVOLOL

DRUGLOSARTAN

DRUGCILAZAPRIL

DRUGVALSARTAN

DRUGMETOPROLOL

DRUGBISOPROLOL

DRUGCANDESARTAN

DRUGENALAPRIL

DRUGLISINOPRIL

DRUGIRBESARTAN

DRUGPERINDOPRIL

DRUGSPIRAPRIL

DRUGCAPTOPRIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Combined endpoint based on the first occurrence of cardiac death and cardiac hospitalization.	—

Secondary

Measure	Time frame
All cardiac hospitalization, Heart failure hospitalization, All cause hospitalization, NT-proBNP, Other predefined (see section plasma and serum biomarkers) biomarkers, Health economic analysis (cost-effectiveness of intervention considering both life- years and quality of life adjusted life years)	—

Countries

Austria, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026